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Abstract
Background:  Since plant extracts are increasingly used as phytotherapeutics or dietary
supplements information on bioavailability, bioefficacy and safety are warranted. We elucidated the
plasma kinetics of genuine extract components and metabolites after single and multiple ingestion
of the standardized maritime pine bark extract Pycnogenol (USP quality) by human volunteers.
Methods: Eleven volunteers received a single dose of 300 mg pine bark extract, five volunteers
ingested 200 mg daily for five days to reach steady state concentrations. Plasma samples were
obtained before and at defined time points after intake of the extract. Samples were analyzed by
HPLC with ion-pair reagents and simultaneous UV and electrochemical detection.
Results: We quantified total plasma concentrations of catechin, caffeic acid, ferulic acid, taxifolin
and the metabolite M1 (δ-(3,4-dihydroxy-phenyl)-γ-valerolactone). Additionally, we describe
plasma time courses and steady state appearance of ten so far unknown compounds, U1 to U10.
After single ingestion, compounds derived from the extract were rapidly absorbed and the majority
of them were detectable over whole experimental period of 14 h. The analysis of steady state
plasma samples revealed significant phase II metabolism.
Conclusion: We present the first systematic pharmacokinetic analysis of compounds derived
from maritime pine bark extract. Beyond the known constituents and metabolites we uncovered
the plasma time courses of ten unknown compounds. In concert with our previous detection of
anti-inflammatory bioefficacy of these plasma samples ex vivo we suggest that constituents and
metabolites of Pycnogenol bear potential for disclosure of novel active principles.
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Background
Since plant extracts are increasingly used as phytothera-
peutics or dietary supplements information on bioavaila-
bility, bioefficacy and safety are warranted. Safety studies
concerning herbal extracts mostly focus on their impact
on metabolic enzyme activity and interactions with
defined chemical drugs [1,2]. Bioefficacy of plant extracts
is progressively investigated in human intervention stud-
ies [3], although there is room for improvement regarding
methodological quality, sample size, and number of trials
[4]. Bioavailability studies are essential completions for
the understanding of risk-benefit values and mode of
action of herbal remedies. Investigations of kinetics and
extent of extract absorption in humans usually focus on a
single or some few known lead compounds [5,6]. Only a
few studies consider kinetics after single and repeated
intake of the respective herbal extract [7,8].
One potential difficulty for the elucidation of both bioa-
vailability and physiological effects of plant extracts is
their varying composition that derives from production
under different protocols or procedures. Therefore, stand-
ardization of the extract is the basis of a reproducible
results and effects that relate to batch, preparation, variety
and species of the plant [9]. One approach towards qual-
ity control of plant extracts is the description of tests, ana-
lytical procedures, and acceptance criteria in monographs
of internationally accepted pharmacopeias, such as the
United States Pharmacopeia (USP). The USP provides the
latest FDA-enforceable standards of quality, identity,
strength, and purity for drug ingredients, dosage forms,
medical devices, and recently also various plant extracts.
An extract with quality specified in the USP 28 is maritime
pine bark extract [10]. A standardized bark extract that
complies with this monograph is derived from of Pinus
pinaster, Ait., (Pycnogenol®, Horphag Research Ltd., UK).
About 65–75 % of the Pycnogenol extract are procyani-
dins that consist of catechin and epicatechin subunits of
varying chain lengths [11]. Other constituents are
polyphenolic monomers, phenolic or cinnamic acids and
their glycosides.
The procyaninidine-rich maritime pine bark extract Pyc-
nogenol exhibited diverse pharmacological actions in
human trials [11]. These effects include, but are not lim-
ited to cardiovascular or anti-inflammatory bioefficacy.
After oral administration to human patients Pycnogenol
exerted effects on circulatory functions such as inhibition
of platelet aggregation, a moderate antihypertensive effect
and improved microcirculation [11,12]. Anti-inflamma-
tory effects of maritime pine bark extract were observed in
asthma patients [13,14].
Though clinical effects of Pycnogenol have been docu-
mented little is known about absorption of extract constit-
uents and their metabolism. After oral administration of
Pycnogenol ferulic acid and taxifolin were detected in
urine after treatment of samples with sulfatase and glu-
curonidase [15]. Both taxifolin and ferulic acid are genu-
ine components of Pycnogenol. In the same experimental
setting two metabolites that were not originally present in
the pine bark extract were identified as δ-(3,4-dihydroxy-
phenyl)-γ-valerolactone and δ-(3-methoxy-4-hydroxy-
phenyl)-γ-valerolactone [15]. Free and conjugated ferulic
acid was also detected in urine samples of volunteers after
intake of Pycnogenol in another study [16]. The authors
suggested ferulic acid as a marker compound for con-
sumption of maritime pine bark extract.
So far, however, no information regarding the time course
of constituents' or metabolites' concentration of Pycnoge-
nol in plasma was available. The purpose of the present
study was to elucidate the kinetics and rate of absorption
of genuine extract components and metabolites after sin-
gle and multiple ingestion of the pine bark extract by
human volunteers. Thereby, we aimed to describe the
time course of known and any so far unknown com-
pounds to generate basic information for understanding
bioavailability and bioefficacy of Pycnogenol.
Methods
Volunteers
Healthy female and male volunteers aged 18 to 30 years
participated in this study. Both study protocols were
approved by the ethical committee of the Comenius Uni-
versity's Faculty of Medicine, Bratislava, Slovak Republic,
and all participants gave written informed consent.
Protocol of single intake of Pycnogenol
Eleven volunteers (five female and six male) participated
in this study. After a 24 hour diet free of flavonoids (no
vegetables, fruits and fruit juices or marmalades, tea, cof-
fee, cocoa, wine and beer) a venous blood catheter was
inserted into an antecubital vein and blood samples were
drawn to obtain basal values (t = 0 h at 8:00 a.m.). Subse-
quently, the volunteers received a single dose of six 50 mg
tablets (preparation of study medication by DKSH, Mar-
ket intelligence, Tokyo, Japan) containing 300 mg stand-
ardized maritime pine bark extract (Pycnogenol®,
Horphag Research Ltd., UK) with 200 mL tap water. At
8:15 a.m. the volunteers had a standardized breakfast
(two white rolls (bread) and 0.3–0.5 L of milk (1.5 %
fat)), at 12:15 lunch (1/4 of only salted and baked chicken
with white bread) and at 6:15 p.m. dinner (100 g ham, 50
g cheese (eidam) and bread with butter or margarine).
After each blood sampling mineral water was served.
Blood samples were obtained at t = 0.5 h, 1 h, 2 h, 4 h, 6
h, 8 h, 10 h, 12 h and 14 h. Samples were centrifuged andBMC Clinical Pharmacology 2006, 6:4 http://www.biomedcentral.com/1472-6904/6/4
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plasma was aliquoted, shock frozen and stored at -80°C
until further analysis.
Protocol of repeated intake of Pycnogenol
Five volunteers (four female and one male) participated
in this study. After a 24 hour diet free of flavonoids blood
samples were drawn to obtain basal values. Subsequently,
the volunteers took four 50 mg tablets containing 200 mg
Pycnogenol every morning for five days to reach steady
state conditions of constituents and/or metabolites of
Pycnogenol. It was assumed that steady state plasma con-
centrations were reached after 5 days.
Four hours after the last intake of Pycnogenol on day five
a second blood sample was obtained from each volunteer.
Again, a 24 hour period of a diet free of flavonoids pre-
ceded this blood sampling. Blood samples were centri-
fuged and plasma was aliquoted, shock frozen and stored
at -80°C until further analysis.
Chemicals and reagents
A spray-dried extract from maritime pine bark (Pycnoge-
nol®) was generously provided by Horphag Research Ltd.
(Geneva, Switzerland). The metabolites M1 (δ-(3,4-Dihy-
droxy-phenyl)-γ-valerolactone) and M2 (δ-(3-Methoxy-4-
hydroxy-phenyl)-γ-valerolactone) were synthesized by
Groβe Düweler[15] The monomeric compounds (+)-cate-
chin, (-)-epicatechin, ferulic acid, gallic acid, 4-hydroxy-
benzoic acid, caffeic acid, protocatechuic acid, sinapic
acid und (±)-taxifolin were purchased from Sigma-Aldrich
(St. Louis, MO, USA). All other chemicals were obtained
from Sigma-Aldrich or Merck (Darmstadt, Germany), if
not stated otherwise. All chemicals used were of highest
purity available.
Krebs-Ringer-HEPES buffer (pH 7.4) consisted of 118 mM
NaCl, 4.84 mM KCl, 1.2 mM KH2PO4, 2.43 mM MgSO4,
2.44 mM CaCl2 × 2 H2O and 10 mM HEPES.
Preparation of plasma samples
Plasma samples of 2.0 mL were prepared for analysis. For
determination of total plasma concentration, to each sam-
ple 20 U β-glucuronidase (type H-3 from Helix pomatia;
EC 3.2.1.31) and 20 U sulfatase (type H-1 from Helix
pomatia; EC 3.1.6.1) were added in 50 mM sodium ace-
tate buffer (pH 5.0) and incubated for 2 h at 37°C under
gentle shaking. Samples for determination of free plasma
concentrations were prepared without prior incubation
with enzymes. Each 20 μL of p-hydroxybenzoic acid
methylester (100 μg/mL; for HPLC UV detection) and
hydrochinone (10 μg/mL; for HPLC electrochemical
detection) were added as internal standards and samples
were acidified with 100 μL 1 M-HCl. Samples were
extracted twice with each 3 mL acetic acid methylester for
20 min, using a roller mixer, followed by centrifugation
(20°C) 5 min. The organic phases of both extractions
were separated, combined and evaporated to dryness
under a gentle stream of nitrogen at 25°C. The resulting
residue was reconstituted in 100 μL methanol and sub-
jected to HPLC analysis.
Calibration curves of all known compounds of Pycnoge-
nol were prepared by addition of the respective substances
to 2.0 mL of Krebs-Ringer-HEPES buffer (pH 7.4). This
was necessary because sufficient volumes of pooled blank
plasma of blood donors who kept a 24 hour diet free of
flavonoids was not available (total volume needed was
about 800 mL for all experiments). Thus, buffer instead of
plasma was used and treated analogously as plasma sam-
ples from volunteers. Since initial control experiments
revealed that the incubation with β-glucuronidase and
sulfatase did not produce interfering peaks in the HPLC
chromatograms no enzymes were added to calibration
curve samples.
Analysis of plasma samples by HPLC – UV/electrochemical 
dual detection
The HPLC system was a Waters HPLC (Milford, MA, USA)
consisted of a 1525 binary pump, a 717plus autosampler,
a 2487 dual wavelength absorbance detector set at the
detection wavelength of 280 nm and an electrochemical
detector CLC 100 (Chromsystems, Munich, Germany) set
at an oxidation voltage of 0.5 V. The second detector was
connected to the control system by a satellite interface
(Waters). Data collection and integration were accom-
plished using Breeze™ software version 3.30. Analysis was
performed on a Zorbax SB C8 column (150 × 4.6 mm I.D.,
5 μm particle size, Agilent Technologies, Palo Alto, CA,
USA).
Typically, 20 μL of sample were injected and separated at
a flow rate of 1 mL/min. Isocratic elution was performed
using water (containing 0.6 mM 1-octanesulfonic acid
sodium salt, 0.27 mM ethylenediaminetetraacetic acid
disodium salt, 0.04 M triethylamine; pH 2.95 adjusted
with phosphoric acid) and acetonitrile (ACN, HPLC gra-
dient quality, Fisher Scientific, Schwerte, Germany).
Method A (for UV detection of ferulic acid, M2 (δ-(3-
Methoxy-4-hydroxy-phenyl)-γ-valerolactone), U1, U2,
U3, U4, U7, U8, and U9) used water/ACN at 85:15 (v/v).
Method B (for electrochemical detection of catechin, caf-
feic acid, taxifolin, M1 (δ-(3,4-dihydroxy-phenyl)-γ-
valerolactone), U1, U2, U4, U5, U6, U8, U9 and U10)
used water/ACN at 88:12 (v/v).
The analytical method was validated according to ICH
guidelines. The method fulfilled the quality criteria for
selectivity, linearity, precision and accuracy. The calibra-
tion curves' working range was 0.5–20 ng/mL for caffeic
acid, 1–50 ng/mL for M1, 10–100 ng/mL for catechin,BMC Clinical Pharmacology 2006, 6:4 http://www.biomedcentral.com/1472-6904/6/4
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taxifolin and ferulic acid, 50–200 ng/mL for M2. The
recovery rates after extraction were 83.1 % (M2) to 98.0 %
(taxifolin). The lower limits of quantitation were 0.5 ng/
mL for caffeic acid, 1 ng/mL for M1, 10 ng/mL for cate-
chin, taxifolin and ferulic acid, 50 ng/mL for M2.
Quantitation of pine bark extract constituents in tablets 
by HPLC – UV detection
Pycnogenol tablets prepared for this study (see above)
were pounded and suspended in methanol to yield con-
centrations of 1 mg/mL, vortexted for 2 minutes, centri-
fuged and the supernatant collected. The procedure was
repeated 4 times. The amount of taxifolin, ferulic acid, caf-
feic acid and catechin in the Pycnogenol tablets adminis-
tered to the volunteers was calculated on the basis of
calibration curves. They were constructed with five con-
centrations ranging from 5–20 μg/mL for taxifolin, from
1–10 μg/mL for ferulic acid, and from 0.1–8 mg/mL for
caffeic acid. Analysis was performed on an Atlantis C-18d
column (150 × 3.9 mm i.d, 3 μm particle size; Waters).
The mobile phase consisted of water containing 1% acetic
acid (A) and acetonitrile (B). The gradient elution started
at 98 % eluent A increasing linearly to 84 % within 60
minutes and a flow rate of 1 mL/min. The UV detection
wavelength was set to 280 nm.
Results
Detection of Pycnogenol constituents and metabolites in 
plasma
After oral ingestion of either a single dose of 300 mg or
multiple doses of 200 mg plasma concentrations of con-
stituents or metabolites of Pycnogenol were detectable in
all volunteers without exception. Unless otherwise indi-
cated, plasma levels repesent the sum of free and conju-
gated compounds. After 300 mg single dose intake a mean
of 11 ± 2 (range 7–14) different constituents or metabo-
lites were found in the plasma samples of each volunteer.
After 200 mg multiple dose intake a mean of 7 ± 2 (range
4–10) different constituents or metabolites were detected
in the plasma sample of each volunteer. A total of 15 dif-
ferent compounds were detectable after single dose
intake. Of those substances detected after single dose
intake, 12 compounds were also found in plasma samples
after multiple dose ingestion.
Of the 15 compounds that were present in plasma sam-
ples 5 were known constituents or metabolites of Pycnog-
enol (catechin, caffeic acid, ferulic acid, taxifolin and M1
(δ-(3,4-dihydroxy-phenyl)-γ-valerolactone), Figure 1).
The other 10 compounds were unknown, they were not
identical with any previously described component of
maritime pine bark extract, e.g. coumaric acid, (-)-epicate-
chin, gallic acid, 4-hydroxybenzoic acid, protocatechuic
acid or M2 (δ-(3-Methoxy-4-hydroxy-phenyl)-γ-valerolac-
tone). The 10 unknown compounds were labelled as U1
to U10 according to their retention time at the reversed-
phase HPLC column. The compound U1 was eluted after
4.5 min, U2 after 5.4 min, U3 after 13.4 min, U4 after
14.3 min, U5 after 15.5 min, U6 after 16.2 min, U7 after
17.2 min, U8 after 20.8 min, U9 after 22.2 min and U10
after 35.8 min. For all unknown substances the peak area
ratios of the respective compound to the internal standard
were calculated which allowed graphical representation of
the time course in plasma.
Pycnogenol constituents and metabolites in plasma after a 
single dose of 300 mg
Compounds with tmax up to 5 hours
Four compounds found in the plasma samples after single
intake of 300 mg Pycnogenol displayed early maximum
concentrations up to five hours and were measurable over
the whole time period of 14 h (Figure 2). Catechin was
detectable rapidly with mean concentrations of about 60
ng/mL after 0.5 h already. Thereafter, the time course
revealed gradually increasing concentrations to about 100
ng/mL after 4 h and subsequent decrease of plasma levels.
However, catechin was detectable over the whole period
of time. The plasma concentrations were almost constant
from 6 to 14 h. A similar time course, but significantly
lower of plasma concentrations were seen for caffeic acid.
Maximum plasma concentrations of ferulic acid were seen
already after 0.5 to 1 h. Concentrations decreased thereaf-
Structural formulas of the known compounds that were  detected in plasma samples of volunteers after intake of Pyc- nogenol Figure 1
Structural formulas of the known compounds that were 
detected in plasma samples of volunteers after intake of Pyc-
nogenol.
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ter and remained almost constant before revealing
another increase towards the end of experimental period.
The unknown compound U10 was present in the plasma
samples after 0.5 h as well, but maximum concentrations
were reached not before 4 h. Thereafter, the plasma levels
steadily decreased and U10 appeared to be almost elimi-
nated after 14 h.
Compounds with tmax between 5 and 10 hours
Three compounds displayed maximum plasma levels
between 5 and 10 h after intake of Pycnogenol tablets
(Figure 3). Taxifolin was not detectable before 2 h, maxi-
mum concentrations were recorded after 8 h. Thereafter,
the taxifolin levels remained almost constant until the
end of the experimental period. Both unknown com-
pounds U8 and U9 appeared rather late after 6 h in
plasma and both were rapidly eliminated with no measur-
able concentrations after 14 h.
Compounds with tmax around 10 hours
Three compounds showed late maximum plasma levels
10 h after intake of Pycnogenol tablets (Figure 4). One
was the previously identified metabolite M1 (δ-(3,4-dihy-
droxy-phenyl)-γ-valerolactone) that has been found in
urine samples before [15]. Consistent with the notion that
it is formed in vivo from catechin by bacterial metabolism
this substance appeared late in plasma. It was detectable
after 6 h, revealed a peak concentration around 10 h
(mean concentration 3.59 ng/mL) and was still present 14
h after Pycnogenol ingestion. Two further compounds of
unknown identity displayed a similar time course with a
tmax around 10 h, but the plasma concentrations of U5
and U6 decreased towards the end of the experimental
period.
Compounds with interindividually highly variable tmax
Five unknown compounds revealed time courses after
intake of Pycnogenol with pronounced interindividual
variability in time of maximum concentrations (Figure 5).
When mean concentrations were calculated, the mean
time course thus appeared to display either no pro-
nounced or multiple tmax, e.g. apparently three tmax for U4.
However, when the time course of the plasma concentra-
tions of individual volunteers was inspected, it revealed
always two tmax, one early tmax between 0.5 to 2 h and one
late tmax between 8 and 12 h. All five substances, U1 to U4
and U7 were detectable over the whole experimental
period. All were readily present in the plasma samples,
Time course of total (free and conjugated) plasma concentrations of catechin, caffeic acid, ferulic acid and U10 Figure 2
Time course of total (free and conjugated) plasma concentrations of catechin, caffeic acid, ferulic acid and U10. These com-
pounds revealed an early tmax (time of maximal plasma concentration) up to five hours after intake of the pine bark extract. 
Symbols represent time course of mean and standard deviation of concentrations after a single dose of 300 mg Pycnogenol. 
The columns represents mean and standard deviation of concentrations after repeated doses of 200 mg Pycnogenol daily after 
five days (assumed steady state). Steady state concentrations of U10 were detectable in only two volunteers and are not 
shown in this diagram.
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especially U3 and U7 revealed high concentrations 0.5 h
after ingestion of Pycnogenol already.
Pycnogenol constituents and metabolites in plasma after 
multiple doses of 200 mg
Most constituents or metabolites that were detected in the
volunteers' plasma samples after intake of a 300 mg single
dose were also found after repeated intake of 200 mg Pyc-
nogenol (columns in Figures 2, 3, 4, 5). Plasma samples
were obtained 4 h after the last dose of Pycnogenol. It was
assumed that steady state conditions were reached after
five days ingestion of the pine bark extract. Steady state
concentrations of all compounds except for taxifolin, U8
and U9 were detectable at least in one volunteer. How-
ever, only when steady state concentrations of a constitu-
ent or metabolite in the plasma of at least three volunteers
were measurable, these are shown as columns in the
graphical plots. Thus, no data are shown for U1 (two
plasma samples with measurable concentrations), U5
(one sample), U6 (two samples), U10 (two samples).
Plasma concentrations of taxifolin, U8 and U9 were
below the limit of quantitation for all volunteers after the
multiple doses of 200 mg. For most compounds the mean
steady state plasma concentration was well within the
range of individual variability in concentrations measured
after single ingestion of the pine bark extract. One excep-
tion is the metabolite M1 which revealed mean steady
state plasma concentrations (3.01 ng/mL) which were
similar to concentrations measured after single intake of
Pycnogenol.
Time course of total (free and conjugated) plasma concentra- tions of M1, U5 and U6 Figure 4
Time course of total (free and conjugated) plasma concentra-
tions of M1, U5 and U6. These compounds had a tmaxaround 
ten hours. Symbols represent time course of mean and 
standard deviation of concentrations after a single dose of 
300 mg Pycnogenol. The column represents mean and stand-
ard deviation of M1 concentrations after repeated doses of 
200 mg Pycnogenol daily after five days. Steady state concen-
trations of U5 and U6 were detectable in one, respectively 
two volunteers and are not shown in this diagram.
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Individual degree of conjugation with sulfate and 
glucuronic acid
The plasma samples obtained after repeated intake of 200
mg Pycnogenol daily were additionally analyzed for the
degree of conjugation with sulfate and glucuronic acid.
This type of phase II metabolism has been described for
Pycnogenol constitutents and metabolites [15,16]. Gener-
ally, the chomatograms of plasma samples that were not
pre-incubated with sulfatase and glucuronidase revealed
less and smaller compound peaks. The degree of conjuga-
tion displayed significant interindividual variability. Data
of compounds that revealed detectable total plasma con-
centrations and a degree of conjugation less than 100 %
are listed in Table 1. For catechin, the range was 0 % con-
jugated (volunteer 4) to ≈ 100 % conjugated (volunteer
3). The other volunteers revealed 43.3 %, 66.8 % and 72.3
% conjugation of catechin (mean percentage of conjuga-
tion 56.5 %). Three volunteers had detectable plasma
concentrations of free caffeic acid. The individual degree
of conjugation was 59.6 %, 61.5 % and 87.6 % (mean
69.4 %). The unknown compound U2 was highly conju-
gated; two volunteers' samples were ≈ 100 % conjugated,
the other 32.4 %, 68.5 % and 84.7 % (mean 77.1 %).
Only three volunteers had detectable plasma concentra-
tions of U7. The individual degree of conjugation was
17.3 %, 46.3 % and 71.4 % for U7 (mean 45 %). Total
Time course of total (free and conjugated) plasma concentrations of U1, U2, U3, U4 and U7 Figure 5
Time course of total (free and conjugated) plasma concentrations of U1, U2, U3, U4 and U7. These compounds revealed high 
interindividual variability of the tmax. Symbols represent time course of mean and standard deviation of concentrations after a 
single dose of 300 mg Pycnogenol. The columns represent mean and standard deviation of concentrations after repeated doses 
of 200 mg Pycnogenol daily after five days. Steady state concentrations of U1 were detectable in only two volunteers and are 
not shown in this diagram.
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plasma concentrations of M1 (n = 3), ferulic acid (n = 3),
U1 (n = 2), U3 (n = 3), U4 (n = 4), U5 (n = 1), U6 (n = 2)
and U10 (n = 2) were detectable in some of the volun-
teers. Since no free concentrations were found we con-
clude that these compounds were about 100 %
conjugated. Plasma concentrations of taxifolin, U8 and
U9 were below the lower limit of quantitation in all vol-
unteers.
Analysis of Pycnogenol in tablets used in the study
The quality of the Pycnogenol tablets used in this study
was analyzed according to the USP 28 monograph [10].
The tablets were in conformity with the acceptance criteria
defined in the monograph. In order to calculate pharma-
cokinetic parameters it was necessary to quantify the con-
tent of known single nonconjugated extract components.
Therefore, the tablets were subjected to HPLC analysis and
content of single compounds was calculated based on cal-
ibration curves with the pure compound. The calculated
content was 1.75 μg free caffeic acid per mg extract in the
study medication, 3.25 μg free ferulic acid per mg extract
and 14.35 μg free taxifolin per mg Pycnogenol.
Pharmacokinetic parameters of compounds detected after 
single dose intake
From individual time courses after administration of 300
mg Pycnogenol as a single dose pharmacokinetic parame-
ters were calculated. Mean and standard deviations of
individual results were summarized (Table 2). For caffeic
acid (calculated dose administered: 0.525 mg), taxifolin
(calculated dose: 4.31 mg) and ferulic acid (calculated
dose: 0.975 mg) the AUC, cmax, tmax and terminal t½ were
determined. These calculations were based on the deter-
mined free concentration of the respective compound in
the extract and based on the assumption that no addi-
tional caffeic or ferulic acid was metabolically generated.
For both catechin and metabolite M1 only cmax and tmax
were calculated. Since unknown amounts of additional
catechin besides genuinely contained monomeric cate-
chin might be generated by metabolic breakdown of
higher procyanidin oligomers [17] no additional parame-
ters could be determined. Likewise, because M1 is gener-
ated from catechin units [15,17] the dose administered
was unknown.
Discussion
In the present investigation we present the results of an
extensive analysis of plasma concentrations of constitu-
ents and metabolites of standardized maritime pine bark
extract (Pycnogenol) after single and multiple administra-
tions to healthy human volunteers. After ingestion, com-
pounds derived from the extract were absorbed by all
volunteers. We quantified the plasma concentrations of
catechin, caffeic acid, ferulic acid, taxifolin and the metab-
olite M1 (δ-(3,4-dihydroxy-phenyl)-γ-valerolactone).
Additionally, we describe plasma time courses and steady
state appearance of ten so far unknown compounds, U1
to U10.
The oral bioavailability of molecules with drug-like prop-
erties depends on their physicochemical properties which
have been described as the "rule of five" [18]. Absorption
is most probable if a compound has less than 5 hydrogen
bond donors, less than 10 hydrogen acceptors, a relative
molecular mass below 500 and a logP smaller than 5.
Exceptions from this rule are known for many orally active
drugs which often share structural similarity with sub-
strates of specific transporters which enable enhanced
absorption. All monomeric polyphenols detected in
plasma samples in the present study comply with the
"rule of five" and thus their bioavailability might not
appear surprising. However, since these genuine com-
pounds of the maritime pine bark extract represent only a
small fraction of the whole extract their presence in
plasma samples substantiates that the excess of higher
procyanidin oligomers does not interfere with absorption
of smaller molecules. Plasma concentrations of caffeic
acid, ferulic acid and taxifolin were well detectable
although the calculated intake of the respective com-
pounds was only between 0.5 and 4 mg after a 300 mg
Pycnogenol dose.
Catechin levels were readily detectable in plasma samples
of the volunteers after single and multiple intake of Pyc-
Table 1: Detectable plasma concentrations of compounds that revealed a mean degree of phase II conjugation of less than 100 %: 
catechin (n = 5), caffeic acid (n = 3), U2 (n = 5) and U7 (n = 3) in samples of volunteers after repeated intake of 200 mg Pycnogenol 
once daily for five days. 
Total plasma concentration Free plasma concentration % conjugated
Catechin [ng/ml] 48.6 ± 16.7 21.0 ± 13.1 56.5 ± 27.9
Caffeic acid [ng/ml] 2.42 ± 1.39 0.56 ± 0.02 69.4 ± 11.8
U2 [peak ratio] 0.0537 ± 0.0132 0.0105 ± 0.0084 77.1 ± 21.3
U7 [peak ratio] 0.0101 ± 0.0007 0.0057 ± 0.0020 45.0 ± 18.5
Plasma concentrations were determined with and without prior incubation of sulfatase and glucuronidase (total and free plasma concentration, 
respectively) and individual percentage of phase II conjugation was calculated. Mean concentrations and mean deviations of the mean are listed.BMC Clinical Pharmacology 2006, 6:4 http://www.biomedcentral.com/1472-6904/6/4
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nogenol as well. It was not possible to determine the
administered "dose" of catechin. Catechin is as well genu-
inely present in the extract as polyphenolic monomer and
might be additionally generated by metabolic breakdown
of higher procyanidin oligomers [17]. In the present study
the catechin plasma concentration peaked with about 100
ng/mL (≈ 370 nmol/L) within the first 3 h. Maximal
plasma concentrations of catechin were observed after 1.5
h in human plasma after ingestion of red wine or recon-
stituted red wine [19,20] and 0.5 h or 2–3 h after intake of
pure catechin [21,22]. Thus, the tmax of catechin observed
in the present investigation is within the range described
in other studies. In contrast to the time course of plasma
levels after ingestion of the pure compound, we observed
catechin over the whole experimental period and the lev-
els remained almost constant between 6 h and 14 h. This
is consistent with metabolic generation of catechin [17]
monomers from oligomeric procyanidins. By 4 h after
ingestion of pure catechin the plasma concentrations were
not significantly different from baseline levels [22]. After
a high single dose the unchanged catechin was detected in
plasma between 30 min and 12 h after administration,
metabolites for a shorter period of time [21]. After a single
dose of pure catechin the free polyphenol concentration
was only 1.1 to 6.5 % of the total concentration. We
observed higher free catechin concentrations of about 56
% after multiple intake of maritime pine bark extract, but
the interindividual variability was high.
Caffeic acid was present in the volunteers' plasma samples
already 0.5 h after ingestion of Pycnogenol. This fast sys-
temic availability is consistent with other reports [6,23-
25]. While we determined a tmax of caffeic acid between 3–
4 h others report tmax values between 0.5–1 h after intake
of red wine, coffee or artichoke leaf extract [6,24,25] or a
tmax 2 h after ingestion of red wine [23]. Though the tmax
we observed appears to be slightly later than in other
investigations the maximal plasma concentrations we
measured were comparatively high. After a calculated
intake of 525 μg caffeic acid a cmax about 17 ng/mL (≈ 90
nmol/L) was found, which is comparable to a cmax of 84
nmol/L after intake of 55 μg caffeic acid per kg body
weight [23]. After ingestion of 107 mg caffeic acid from
artichoke leaf extract a lower cmax  of 6.5 ng/mL was
reported [6]. The later tmax and higher cmax found in the
present study might indicate additional sources of caffeic
acid from so far not identified metabolic pathways or due
to the presence of additional caffeic acid as conjugate in
the pine bark extract. A 5.4 fold increase of caffeic acid
concentration in beer after hydrolysis was recently
described [26]. The elimination half-live of 4.42 ± 2.47 h
we calculated for caffeic acid is consistent with the t½ of
3.08 ± 1.53 h reported previously [6]. The degree of con-
jugation of caffeic acid we found after multiple intake of
the maritime pine bark extract (mean 69 %) was within
the range reported after single intake of coffee (around
70–80 %) [25], but lower than after or after beer ingestion
(around 90 %) [26].
Ferulic acid has been previously described as a urine excre-
tion marker of consumption of maritime pine bark extract
[16] and thus it was expected to be present in plasma. We
observed an early tmax of 1 h for ferulic acid which is con-
sistent with other reports of tmax values of 1–3 h [27] or
0.77 h [6]. The cmax of about 15 ng/mL (≈ 75 nmol/L) we
observed after intake of the single dose Pycnogenol con-
taining 975 μg free ferulic acid again appears to be high.
After ingestion of 250 mg ferulic acid from breakfast cere-
als plasma concentrations of 150–210 nmol/L were
described [27]. However, additional ferulic acid might be
present in the pine bark extract in conjugated form and it
is known to be generated in vivo by methylation of caffeic
acid [6,16]. The fact that the plasma concentrations of fer-
ulic acid are almost constant between 2 h and 14 h favour
the notion of additionally generated ferulic acid, e.g. from
caffeic acid. The remarkably high steady state concentra-
tions of ferulic acid (about 20 ng/mL) after repeated
intake of Pycnogenol along with the rather low steady
state concentrations of caffeic acid furthermore support
the concept of metabolic generation of ferulic acid. The
elimination half-live of ferulic acid we calculated (6.87 ±
3.83 h) is completely consistent with the t½ of 6.35 ± 2.95
Table 2: Calculated pharmacokinetic parameters of components or metabolites after intake of a single dose of 300 mg Pycnogenol. 
Values represent means and standard deviations. 
Compound n AUC [0-t] [ng/mL × h] AUC [t-8] [ng/mL × h] cmax [ng/mL] tmax [h] term t½ [h]
Caffeic acid 9 75.66 ± 33.53 82.78 ± 36.47 16.67 ± 13.29 3.7 ± 2.4 4.42 ± 2.47
Catechin 9 107.22 ± 55.49 3.2 ± 1.7
Taxifolin 6 231.11 ± 85.98 399.14 ± 98.95 33.34 ± 12.54 8.2 ± 2.5 8.89 ± 2.81
Ferulic acid 7 99.05 ± 28.09 141.19 ± 73.90 14.78 ± 5.89 1.2 ± 1.1 6.87 ± 3.83
M1 8 4.11 ± 2.08 10.0 ± 1.9
Abbreviations: n – number of volunteers with detectable compound concentrations; AUC – area under the curve, "t" symbolizes the time of last 
plasma sampling (14 h); cmax – maximal plasma concentration, tmax – time of maximal plasma concentration; term t½ – terminal half-life of 
compound.
These calculations were based on the determined free concentration of the respective compound in the extract and based on the assumption that 
no additional caffeic or ferulic acid was metabolically generated.BMC Clinical Pharmacology 2006, 6:4 http://www.biomedcentral.com/1472-6904/6/4
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h reported by Wittemer et al. [6]. In our study we did not
detect any free, only conjugated ferulic acid after repeated
intake of maritime pine bark extract whereas around 25 %
free ferulic acid was found after single ingestion of beer
[26].
Taxifolin was detected not before 2 h after ingestion of the
pine bark extract and maximal plasma concentrations
were recorded after 8 h. Furthermore, no steady state con-
centrations of conjugated or free taxifolin were detectable
after multiple intake of Pycnogenol. This plasma concen-
tration profile of taxifolin was quite unexpected since free
taxifolin is present in the extract at higher concentrations
than other polyphenol monomers. To our knowledge, no
plasma concentrations of taxifolin have been reported for
humans before. We supposed that the compound's late
appearance in plasma and the lack of steady state levels is
due to metabolic degradation processes. The anaerobic
bacterium Clostridium orbiscindens was found in human
feces recently [28]. This bacterium has the ability to
degrade taxifolin to 3,4-dihydroxyphenylacetic acid and
phloroglucin. However, we failed to detect either of these
metabolites in the volunteers' plasma samples.
The catechin metabolites M1 (δ-(3,4-dihydroxy-phenyl)-
γ-valerolactone) and M2 (δ-(3-Methoxy-4-hydroxy-phe-
nyl)-γ-valerolactone) have been previously found in urine
samples after oral intake of maritime pine bark extract
[15] and thus we expected their presence in plasma sam-
ples as well. However, we only detected the metabolite M1
after intake of a single dose and after repeated ingestion of
Pycnogenol. Since cmax concentrations of M1 were only
around 4 ng/mL (≈ 20 nmol/L) after single and repeated
dosing we assume that our analytical method was not sen-
sitive enough to detect M2 (lower limit of quantitation: 50
ng/mL). Consistent with the information that M1 is gen-
erated from catechin units [15,17] we observed at late tmax
10 h after ingestion of the extract. Peak plasma levels of
M1 were observed 5–12 h after ingestion of green tea [29]
and earliest appearance of M1 has been recorded after 3 h
after green tea ingestion [30].
Along with the above discussed five known constituents
or metabolites of Pycnogenol ten so far unknown com-
pounds were found in the volunteers' plasma samples.
These substances are not identical to any other known free
polyphenol monomer in the maritime pine bark extract.
They may, however, be conjugates of monomers or
metabolites of higher procyanidin oligomers. It is also
conceivable that a procyanidin dimer is among these
unknown compounds. The procyanidin B1 has been
detected in human plasma samples [31] and this procya-
nidin is a constituent of Pycnogenol as well. The
unknown compound U10 displays a tmax 4 h after inges-
tion of the extract. Based on this time course it is very
likely that U10 is a constituent rather than a metabolite of
Pycnogenol. In contrast, it can be assumed that the com-
pounds U8 and U9 which are detectable only between 8 h
and 10 h are metabolites which are either rapidly elimi-
nated or further metabolized. Consequently, these are the
only compounds besides taxifolin which are not present
in the steady states plasma samples of a single volunteer.
The compounds U5 and U6 display typical plasma pro-
files of metabolites as well since they cannot be discovered
before 6 h or 8 h, respectively, after ingestion of Pycnoge-
nol. The unknown compounds U1, U2, U3, U4 and U7
were all readily detectable in plasma after 0.5 h and all
revealed an essentially biphasic plasma concentration
profile. Although the individual tmax values vary consider-
ably all substances have one early and one late tmax. Mul-
tiple tmax values are consistent with either enterohepatic
circulation of a compound or with successive metabolic
generation of additional substance, e.g. by breakdown of
higher procyanidin oligomers.
Regarding the plasma time course of constituents or
metabolites of Pycnogenol two observations are remarka-
ble. One is that apparently many constituents are bioa-
vailable after oral ingestion and obviously pronounced
metabolism occurs. The other fact is that the concentra-
tions of known compounds both after single and multiple
dosing are within the ng/mL range translating into
nanomolar concentrations. This appears to be very low
and reminds of a question brought up by Goldberg et al.
[22] whether biologically effective polyphenol concentra-
tions are attainable in humans. We previously elucidated
the effects of two Pycnogenol metabolites, M1 and M2,
towards inhibition of activity and release of matrix metal-
loproteinases (MMP) in vitro and in cell culture assays
[32]. We found that both metabolites were effective in
inhibition of MMP-9 release with IC50 values of 0.5 μM. In
the present study we learned that these concentrations
were not detected in the volunteers' plasma samples. Var-
ious conclusions are possible; one is that the in vitro exper-
iments are irrelevant because concentrations required for
e.g. anti-inflammatory effects are not attained in vivo.
Opposing this view is the fact that Pycnogenol has dem-
onstrated in vivo efficacy in various clinical studies [3,11].
Another conclusion might be that various substances act
synergistically and thus efficacy is seen at lower levels of
the individual compound. However, so far there are no
proofs for this. A last conclusion we would like to suggest
is that we possibly have been looking for the wrong com-
pounds. While most in vitro studies focused on free
polyphenolic monomers it has been reported that the
conjugates might exert effects as well [33,34]. Our present
study furthermore indicates that multiple unknown con-
stituents and/or metabolites are present in plasma sam-
ples after ingestion of maritime pine bark extract. These
might well be responsible for the pharmacodynamicBMC Clinical Pharmacology 2006, 6:4 http://www.biomedcentral.com/1472-6904/6/4
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effects of Pycnogenol. Our recent results support the sug-
gestion that active principles with significant bioefficacy
are present in plasma of human volunteers after ingestion
of the extract. Aliquots of plasma samples from the volun-
teers of the present study were previously assayed for their
effects towards cyclooxygenase (COX) activity [35]. The
plasma samples after multiple intake of Pycnogenol
revealed moderate, but no significant inhibition of COX-
1 and COX-2. In contrast, plasma samples obtained 0.5 h
after ingestion of the extract significantly inhibited both
COX enzymes. We also employed the steady state plasma
samples in cell culture assays. Although these plasma sam-
ples were diluted 1:1 with cell culture medium they still
moderately inhibited NF-κB activation and significantly
inhibited release of MMP-9 from activated human mono-
cytes [36]. Consequently, we now have to identify the
unknown compounds detected after Pycnogenol intake
and elucidate their anti-inflammatory activities.
Conclusion
We present the first systematic pharmacokinetic analysis
of constituents and metabolites of the standardized mari-
time pine bark extract (USP quality) after single and
repeated intake by human volunteers. Components of the
extract were bioavailable and detectable in the plasma of
all subjects. Pharmacokinetic parameter calculated for the
so far identified compounds were comparable with results
from other studies. In addition, for the first time we
describe steady state concentrations of catechin, caffeic
acid, ferulic acid and M1 (δ-(3,4-dihydroxy-phenyl)-γ-
valerolactone) and present the first taxifolin plasma con-
centrations in humans. The detection of ten so far
unknown bioavailable constituents and metabolites of
Pycnogenol reveal potential for uncovering active com-
pounds with anti-inflammatory bioefficacy.
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